QUICKLINKS AND VIEW OPITONS
Belviq (lorcaserin) should be discontinued if patients do not lose at least 5% in 3 months
Wednesday, June 27, 2012 10:40 am Email this article
"The approved labeling for Belviq recommends that the drug be discontinued in patients who fail to lose 5 percent of their body weight after 12 weeks of treatment [3 months], as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment," according to the Press Release from the U.S. Food and Drug Administration.The drug was approved by the FDA on June 27, 2012.
Fda. Fda approves belviq [lorcaserin hydrochloride] to treat some overweight or obese adults. FDA News Press Release. 2012 Jun 27,
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.